RBC Europe’s Maravai LifeSciences MRVI Stock Holding History

RBC Europe’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-145	Closed	-$6K	–	654
2021 Q4	$6K	Buy	+145	New	+$5.87K	﹤0.01%	554

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RBC Europe's MRVI Position: Q1 2022 in Review

RBC Europe sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 145 shares — an estimated $6K sold.

RBC Europe first reported a position in MRVI in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

RBC Europe reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
RBC Europe sold 145 Maravai LifeSciences shares in Q1 2022, an estimated $6K.
RBC Europe first reported a position in Maravai LifeSciences in Q4 2021 and held it in 1 quarter.
RBC Europe's Maravai LifeSciences position peaked at $6K in Q4 2021.
235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on RBC Europe's 13F filing for Q1 2022, filed 14 Nov 2022.